Mucopolysaccharidosis is a metabolic disorder caused by missing or deficient enzymes needed to break down the keratan sulfate sugar chain. It is physically manifested through skeletal abnormalities, such as a flattening or curvature of the spine and dysplasia of the hips and knees.
Vimizim was also granted a priority review designation, a designation given to drugs that offer major treatment advances, according to the report.
More Articles on Devices:
ECA Medical Instruments Moves Into 24k-Square-Foot Headquarters
K2M Internationally Launches Spinal Device for Small Stature Patients
Spinal Elements Receives Licenses on Portfolio of Lateral Lumbar Spine Approaches
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
